Trial Profile
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 23 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Sep 2017 Primary endpoint (Percentage of subjects with detectable circulating T cells after treatment) has not been met, according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 26 Sep 2017 Results assessing effects of ipilimumab when added to neoadjuvant chemotherapy (paclitaxel + carboplatin + cisplatin) on levels of detectable circulating T cells with specificities against tumour-associated antigens (TAA) in patients with treatment-naive stage IB or II non-small cell lung cancer, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.